Research Interests
Endotheliopathies post Transplant; critical care complications of PTCT;
Selected Grants
A Phase 1/2, Open-Label, Basket Study of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2024 - 2038A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR¿ss+/CD19+ depleted transplantation
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2029Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants with X-Linked Chronic Granulomatous Disease
Clinical TrialPrincipal Investigator · Awarded by Ensoma, Inc. · 2025 - 2027EAP for 5613 patients with relapsed/refractory acute leukemias with genetic alterations w/ HOXA
Clinical TrialPrincipal Investigator · Awarded by Syndax Pharmaceuticals Inc · 2024 - 2027Cohort Study of SNDX-5613
Clinical TrialPrincipal Investigator · Awarded by Syndax Pharmaceuticals Inc · 2023 - 2026A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases
Clinical TrialPrincipal Investigator · Awarded by Fate Therapeutics Inc. · 2025 - 2026Prospective Multi-Center Study of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and /or Multi-Organ Dysfunction Syndrome (MODS)
ResearchPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2023 - 2026A Phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-gener
Clinical TrialPrincipal Investigator · Awarded by Children's Hospital Los Angeles · 2023 - 2025External Relationships
- Gamida-Cell, Ltd.
- Jazz Pharmaceuticals
- Sobi Pharmaceuticals
- Vertex Pharmaceuticals Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.